C-144

In Vitro Activity of Ceftazidime-Avibactam (CAZ-AVI) and Comparators Against Gram-negative Pathogens Isolated from Patients in Canadian Hospitals in 2009-2014: CANWARD Surveillance Study

P. LAGACÉ-WIENS[1,2], H. ADAM[1,2], A. DENISUIK[1], M. BAXTER[1], J. KARLOWSKY[1,2], A. WALKTY[1,2], D. HOBAN[1,2], G. G. ZHANEL[1]
and the CANADIAN ANTIMICROBIAL RESISTANCE ALLIANCE (CARA)
[1]University of Manitoba, [2]Diagnostic Services Manitoba, Winnipeg, Canada

Philippe Lagacé-Wiens
L4025-409 Taché Ave.
Winnipeg, MB, CANADA
+1-204-237-2483
plagacewiens@dsmanitoba.ca

Health Sciences Centre Winnipeg

DIAGNOSTIC SERVICES MANITOBA | SERVICES DIAGNOSTIC MANITOBA

CANADIAN ANTIMICROBIAL RESISTANCE ALLIANCE CARA
www.can-r.ca

UNIVERSITY OF MANITOBA

ABSTRACT

Background: Avibactam, a β-lactamase inhibitor of Ambler class A, C and some class D enzymes in combination with ceftazidime, is FDA approved for the treatment of complicated urinary tract and intra-abdominal infections in adults. We determined the in vitro activity of ceftazidime (CAZ) with avibactam (fixed 4 µg/mL concentration) and comparators versus Gram-negative pathogens, including extended-spectrum β-lactamase producing (ESBL), AmpC-producing (AmpC) *Enterobacteriaceae* and *Pseudomonas aeruginosa* isolates recovered from January 2009 to October 2014 from patients in medical and surgical wards, intensive care units, clinics, and emergency rooms at 15 Canadian hospitals.

Methods: Antimicrobial susceptibility testing was performed using broth microdilution panels following CLSI recommendations (M07-A10). Susceptibility was defined in accordance with CLSI, except for CAZ-AVI, where the FDA breakpoints were used. Cephalosporin-resistant *Escherichia coli* and *Klebsiella* spp. isolates were genetically characterized for ESBL-production using PCR and sequence analysis.

Results: The activity of CAZ-AVI and comparators is summarized in Table 1 and 2.

Conclusions: CAZ-AVI demonstrated potent in vitro activity against recent clinical isolates of *Enterobacteriaceae*, including those with resistance to oxyminocephalosporins by a variety of mechanisms. MIC_{90} of CAZ-AVI against *P. aeruginosa* was comparable to meropenem and 4 fold lower than CAZ alone. CAZ-AVI was the most active agent against CAZ, MER and TZP-resistant *P. aeruginosa*. Activity against *A. baumannii* was not improved compared to CAZ alone. Activity against *S. maltophilia* was poor but somewhat better than CAZ alone. CAZ-AVI may be useful for the treatment of infections caused by β-lactam-resistant *Enterobacteriaceae* and *P. aeruginosa*.

BACKGROUND

Antimicrobial resistance is a growing problem among Gram-negative isolates worldwide. Multi-drug resistant (MDR) *P. aeruginosa*, ESBL-, KPC- and AmpC-producing *Enterobacteriaceae*, and MDR *Acinetobacter* spp. can cause severe infections and treatment choices are limited. Avibactam is a broad-spectrum non-β-lactam β-lactamase inhibitor being studied in combination with ceftazidime to restore the parent drug activity against a wide range of cephalosporin-resistant Gram-negative pathogens expressing Ambler class A and C, and some class D, β-lactamases (1).

MATERIALS & METHODS

Isolates were collected as part of the CANWARD 2009 through to CANWARD 2014 studies occurring between January 2009 and October 2014. 15 Canadian centers in 8 provinces contributed clinically relevant isolates. Only species with >100 isolates submitted were considered in this study. A total of 9586 Gram-negative isolates were included. Susceptibility testing was done by broth microdilution in accordance with the CLSI M07-A10 document (2). Serial dilutions of ceftazidime with and without a fixed concentration of 4 µg/mL avibactam, piperacillin-tazobactam, ceftriaxone, meropenem and tigecycline were included on the panel. Susceptibility was defined in accordance with CLSI, except for CAZ-AVI, where the FDA breakpoints were used. Cephalosporin-resistant *Escherichia coli* and *Klebsiella* spp. isolates were genetically characterized for ESBL-production using PCR and sequence analysis.

RESULTS

TABLE 1: MIC_{50} and MIC_{90} for all isolates and cephalosporin-resistant isolates for ceftazidime-avibactam and comparators.

Organism (n)	MIC_{50}/MIC_{90} (µg/mL)				
	Ceftazidime-Avibactam	Ceftazidime	Ceftriaxone	Meropenem	Piperacillin-tazobactam
Escherichia coli (4533)	0.12/0.25	≤0.25/1	≤0.25/0.5	≤0.03/≤0.03	2/4
E. coli CRO-R (372)	0.12/0.5	16/>32	64/>64	≤0.03/≤0.03	4/16
E. coli ESBL (295)	0.12/0.5	16/>32	>64/>64	≤0.03/≤0.03	4/16
Pseudomonas aeruginosa (2168)	2/8	4/32	16/>64	0.5/8	4/64
P. aeruginosa (CAZ-R) (251)	8/>16	>32/>32	>64/>64	4/32	128/512
P. aeruginosa (TZP-R) (155)	8/>16	>32/>32	>64/>64	8/32	256/512
P. aeruginosa (MER-R) (258)	8/16	16/>32	>64/>64	16/>32	32/256
Klebsiella pneumoniae (1472)	0.12/0.5	≤0.25/1	≤0.25/≤0.25	≤0.03/≤0.03	2/8
K. pneumoniae CRO-R (68)	0.5/2	32/>32	64/>64	≤0.03/0.25	8/512
K. pneumoniae ESBL (62)	0.5/2	32/>32	64/>64	≤0.03/0.12	8/>512
Enterobacter cloacae (598)	0.25/1	0.5/>32	≤0.25/>64	≤0.03/0.12	2/64
E. cloacae CRO-R (144)	0.5/2	>32/>32	>64/>64	0.06/0.25	32/128
E. cloacae ERT-R (21)	0.5/4	>32/>32	>64/>64	0.5/2	64/256
Serratia marcescens (373)	0.25/0.5	≤0.25/1	≤0.25/1	0.06/0.06	≤1/4
Klebsiella oxytoca (379)	0.12/0.5	≤0.25/0.5	≤0.25/1	≤0.03/≤0.03	2/128
Proteus mirabilis (352)	≤0.06/0.1	≤0.25/≤0.25	≤0.25/≤0.25	0.06/0.12	≤1/≤1
Enterobacter aerogenes (168)	0.25/0.5	0.5/>32	≤0.25/16	≤0.03/0.12	4/32
Acinetobacter baumannii (104)	8/32	8/>16	8/64	0.5/1	≤1/64
Stenotrophomonas maltophilia (370)	>32/>32	>16/>16	>64/>64	>32/>32	256/>512

CRO-R: Ceftriaxone-resistant; MER-R Meropenem-resistant, CAZ-R: Ceftazidime-resistant; TZP-R: piperacillin-tazobactam resistant, ERT-R: Ertapenem-resistant , ESBL: Extended spectrum β-lactamase-producing

TABLE 2: Percent susceptible for all isolates and cephalosporin-resistant isolates to ceftazidime-avibactam and comparators.

Organism (n)	% Susceptible				
	Ceftazidime-Avibactam[1]	Ceftazidime[2]	Ceftriaxone[2]	Meropenem[2]	Piperacillin-tazobactam[2]
Escherichia coli (4533)	100	93.8	91.6	100	97.8
E. coli CRO-R (372)	99.7	30.1	0	99.7	91.7
E. coli ESBL (295)	99.7	34.2	2.7	99.7	93.2
Pseudomonas aeruginosa (2168)	94.4	82.5	N/A	80.5	84.5
P. aeruginosa (CAZ-R) (251)	66.9	0	N/A	45.8	11.2
P. aeruginosa (TZP-R) (155)	67.7	1.9	N/A	41.3	0
P. aeruginosa (MER-R) (258)	74.4	39.9	N/A	0	43.8
Klebsiella pneumoniae (1472)	100	96.1	95	99.7	97.4
K. pneumoniae CRO-R (68)	100	4.4	0	94.1	64.7
K. pneumoniae ESBL (62)	100	4.8	6.5	96.8	64.5
Enterobacter cloacae (598)	99.7	77.8	73.7	99.2	86.0
E. cloacae CRO-R (144)	98.6	9.7	0	96.5	41.7
E. cloacae ERT-R (21)	90.5	4.8	0	76.2	28.6
Serratia marcescens (373)	100	99.5	94.1	99.5	95.7
Klebsiella oxytoca (379)	100	98.7	91.3	100	88.1
Proteus mirabilis (352)	100	99.4	98.3	100	100
Enterobacter aerogenes (168)	99.4	76.2	72.6	99.4	88.0
Acinetobacter baumannii (104)	N/A*	78.9	51.0	95.2	84.6
Stenotrophomonas maltophilia (370)	N/A**	23.8	N/A	N/A	N/A

CRO-R: Ceftriaxone-resistant; MER-R Meropenem-resistant, CAZ-R: Ceftazidime-resistant; TZP-R: piperacillin-tazobactam resistant, ERT-R: Ertapenem-resistant , ESBL: Extended spectrum β-lactamase-producing
[1]FDA breakpoints. [2]CLSI M100-S25 breakpoints. *61.5% of isolates had MIC ≤ 8µg/mL. **31.6% of isolates had MIC ≤ 8µg/mL.

CONCLUSIONS

Avibactam reduced MIC_{50} and MIC_{90} of ceftazidime for all organisms tested except *A. baumannii* and *S. maltophilia.*

Avibactam restored the activity of ceftazidime for all *Enterobacteriaceae* with acquired resistance to ceftriaxone.

Avibactam resulted in a 2-fold reduction in MIC_{50} and 4-fold reduction in MIC_{90} compared with ceftazidime alone for *P. aeruginosa*.

Ceftazidime-avibactam susceptibility rates are >99% for all *Enterobacteriaceae* (77.8 - 99.2% for ceftazidime alone), 94.4% for *P. aeruginosa* (82.5% for ceftazidime alone) and 61.5% (using the ceftazidime breakpoint) for *A. baumannii* (78.9% for ceftazidime alone).

Ceftazidime-avibactam susceptibility rates are comparable with meropenem for *Enterobacteriaceae*, superior to meropenem for *P. aeruginosa.*

ACKNOWLEDGMENTS

We acknowledge the contributions of the directors and technologists of the contributing site microbiology laboratories.

This study was supported in part Abbott Laboratories Ltd, Affinium, Astellas, AstraZeneca, Cerexa/Forest, Cubist, Merck Canada, Pfizer, Sunovion, and The Medicines Company.

REFERENCES

1. Lagacé-Wiens et al. Activity of NXL104 in Combination with β-Lactams against Genetically Characterized *Escherichia coli* and *Klebsiella pneumoniae* Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases. Antimicrob. Agents Chemother. 2011. 55:2434-2437.
2. CLSI. *Methods for Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard – Eighth Edition.* CLSI document M07-A10. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
3. CLSI. *Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement.* CLSI document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.